Ocugen to Present at Industry and Investor Conferences in October 2025

Core Insights - Ocugen, Inc. is actively participating in key industry conferences to showcase its advancements in gene therapies for blindness diseases and aims to achieve three Biologics License Applications (BLAs) within the next three years [2][5] Group 1: Conference Participation - Ocugen's executive leadership will present at the 2025 Cell & Gene Meeting on the Mesa, Chardan's 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit [1][4] - Dr. Shankar Musunuri, Chairman and CEO, will engage in discussions about the company's progress and potential partnerships during these events [2][4] - Specific presentation details include: - Cell & Gene Meeting on the Mesa: October 6, 2025, at 4 p.m. MST in Phoenix, AZ [3] - Chardan's 9th Annual Genetic Medicines Conference: October 21, 2025, from 9:30-10:10 a.m. EDT in New York, NY [3] - 2025 Maxim Growth Summit: October 22, 2025, from 3-4 p.m. EDT in New York, NY [4] Group 2: Company Overview - Ocugen is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [5] - The company is developing therapies for inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [5]